Skip to main content

Table 1 Descriptive characteristics of the study patients (N = 76)

From: Clinical outcome of patients with differentiated thyroid cancer and raised antithyroglobulin antibody levels: a retrospective study

Variables Mean Median Percentile (Q1, Q3)
Age (years) at diagnosis 35.71 ± 14.01 34 25, 45
Time between Surgery and RIT 3.64 ± 1.65 3.0 3, 4.8
RIT (mCi) 66.05 ± 41.12 60.0 30,100
Tg Baselinea 5.98 ± 16.78 0.27 20, 2.80
Tg after RITa 0.66 ± 1.24 0.20 0.20, 0.79
TgAb (baseline)b 713.29 ± 1073.6 166.50 70, 675.3
TgAb after RITb 420.23 ± 830.56 103.0 10,339.5
TgAb (% change, Baseline-early follow up) −34.29 ± 68.62 −47.57 −78.97, −11.96
TgAb (final)b 450.42 ± 1185.20 53.0 10, 245.5
TgAb (% change, Baseline-last follow up) −52.62 ± 53.16 −73.48 −86.90, −33.40
Follow up Duration (months) 58.74 ± 26.26 55 42.30, 71.8
  1. RIT High dose Radiodiodine Therapy, Tg Serum Thyroglobulin, TgAb Serum Antithyroglobulin antibody
  2. aTg level expressed in ng/dl
  3. bTgAb level expressed in IU/ml